Useful in the assessment of chronic exposure and determination of cadmium body burden. For acute exposure, Cadmium, Blood (0099675) is preferred.
Quantitative Inductively Coupled Plasma-Mass Spectrometry
Diet, medication, and nutritional supplements may introduce interfering substances. Patients should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician). High concentrations of iodine may interfere with elemental testing. Abstinence from iodine-containing medications or contrast agents for at least 1 month prior to collecting specimens for elemental testing is recommended.
24-hour or random urine collection. Specimen must be collected in a plastic container. ARUP studies indicate that refrigeration of urine alone, during and after collection, preserves specimens adequately, if tested within 14 days of collection.
Transfer an 8 mL aliquot from a well-mixed collection to ARUP Trace Element-Free Transport Tubes (ARUP supply #43116). Available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 1 mL)
Refrigerated. Also acceptable: Room temperature or frozen.
Urine collected within 48 hours after administration of a gadolinium (Gd) containing contrast media (may occur with MRI studies). Acid preserved urine. Specimen contaminated with blood or fecal material. Specimens transported in non-trace element free transport tube (with the exception of the original device).
Trace Elements requisition form may be required (ARUP form #32990-Barcode; #32991-No Barcode). Record total volume and collection time interval on transport tube and on test request form.
Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 1 year
Effective November 13, 2017
|Cadmium, Urine - per volume||0.0-1.0 µg/L|
|Cadmium, Urine - per 24h||0.0-3.2 µg/d|
|Cadmium, Urine - ratio to CRT||0.0-3.2 µg/g crt|
|Creatinine, Urine - per 24h||
Urine cadmium levels can be used to assess cadmium body burden. In chronic exposures, the kidneys are the primary target organ. Symptoms associated with cadmium toxicity vary based upon route of exposure and may include tubular proteinuria, fever, headache, dyspnea, chest pain, conjunctivitis, rhinitis, sore throat and cough. Ingestion of cadmium in high concentration may cause vomiting, diarrhea, salivation, cramps, and abdominal pain.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
|0020207||Creatinine, Urine - per volume||2161-8|
|0020208||Creatinine, Urine - per 24h||2162-6|
|0025038||Cadmium, Urine - ratio to CRT||13828-9|
|0025041||Cadmium, Urine - per 24h||5612-7|
|0025042||Cadmium, Urine - per volume||5611-9|